Combination chemotherapy for hepatitis B virus: The path forward?

Drugs

Volumn 60, Issue 3, 2000, Pages 517-531

  Shaw, T ^a   Locarnini, S ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; BETA 2,6 DIAMINOPURINE DIOXOLANE; CLEVUDINE; DEOXYGUANOSINE DERIVATIVE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; HEPATITIS B ANTIBODY; LAMIVUDINE; LOBUCAVIR; NUCLEOSIDE DERIVATIVE; PENCICLOVIR; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; VIDARABINE;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; MATHEMATICAL MODEL; META ANALYSIS; PHASE 3 CLINICAL TRIAL; REVIEW; VIRUS REPLICATION;

DNA VIRUSES; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0033781615     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060030-00001     Document Type: Review

References (132)

1. Hepatitis B virus
2. Strategies to prevent and control hepatitis B and C virus infections: A global perspective
3. Update on diagnosis, management, and prevention of hepatitis B virus infection
4. Hepatitis B virus infection
5. Hepatitis B virus in hepatocarcinogenesis
6. Hepatitis B virus infection and hepatocellular carcinoma: Molecular genetics and clinical perspectives
7. Plasma carotenoids, glutathione S-transferase M1 and T1 genetic polymorphisms, and risk of hepatocellular carcinoma: Independent and interactive effects
8. Hepatic purine and pyrimidine metabolism: Implications for antiviral chemotherapy of viral hepatitis
9. A practical guide to the use of interferons in the management of hepatitis virus infections
10. Long-term results with interferon therapy in chronic type B hepatitis: A prospective randomized trial
11. Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon
12. Long-term follow-up of a randomized trial of interferon therapy for chronic hepatitis B in a predominantly homosexual male population
13. Treatment of chronic viral hepatitis
14. The identification and development of antiviral agents for the treatment of chronic hepatitis B virus infection
15. Perspectives for the treatment of hepatitis B virus infections
16. Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues
17. Lamivudine. A review of its therapeutic potential in chronic hepatitis B
18. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group
19. Evaluation of the potent anti-hepatitis B virus agent (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model
20. Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus
21. Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent
22. Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection
23. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir
24. A transgenic mouse lineage useful for testing antivirals targeting hepatitis B virus
25. A phase 2 multicentre trial of oral lobucavir for treatment of chronic hepatitis B
26. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection
27. Famciclovir treatment of chronic hepatitis B in heart transplant recipients: A prospective trial
28. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells
29. DAPD, a novel inhibitor of hepatitis B virus replication
30. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: Two placebo-controlled phase II studies
31. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection
32. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection
33. The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues
34. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues
35. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure
36. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance
37. Two novel antiviral agents, DAPD and L-FMAU, which are active against wild-type and lamivudine-resistant HBV
38. Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir
39. Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation
40. Oral ganciclovir treatment in chronic hepatitis B virus infection: A pilot study
41. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
42. Mutations in hepatitis BDNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
43. Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis
44. Adenine arabinoside 5'-monophosphate in patients with chronic hepatitis B: Comparison of the efficacy in patients with high and low viral replication
45. Therapy of chronic hepatitis B with a 6-month course of ribavirin
46. The antiviral compound ribavirin modulates the T helper [Th] 1/Th2 subset balance in hepatitis B and C virus-specific immune responses
47. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: A randomized, controlled trial
48. Thymosin alphal treatment of chronic hepatitis B results of a phase III multicentre, randomized, double-blind and placebo-controlled study
49. Hepatitis B immune globulin: Evaluation of clinical trials and rationale for usage
50. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: Final report of a randomized double-blind, placebo-controlled trial
51. Significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogues and implications for controlling chronic disease
52. Novel molecular approaches toward therapy of chronic hepatitis B
53. Summary of the third International Consensus Symposium on Combined Antiviral Therapy
54. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy
55. Anti-human immunodeficiency virus drug combination strategies
56. Antiviral chemotherapy for chronic hepatitis B infection: Lessons learned from treating HIV-infected patients
57. Hepatitis B virus replication: An update
58. Interactions of the human immunodeficiency virus and the hepatotropic viruses
59. A combinatorial ledge: Reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance
60. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
61. Quasispecies structure and persistence of RNA viruses
62. The frequency of resistant mutant virus before antiviral therapy
63. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients
64. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection
65. Prevalence and significance of naturally occurring mutations in the surface and polymerase genes of hepatitis B virus
66. Selection of hepatitis B surface 'escape' mutants during passive immune prophylaxis following liver transplantation: Potential impact of genetic changes on polymerase protein function
67. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin
68. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
69. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
70. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine: Lamivudine Clinical Investigation Group
71. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient
72. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: Durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin
73. Constrained evolution with respect to gene overlap of hepatitis B virus
74. Molecular evolution of the hepatitis B virus genome
75. Relationships within and between genotypes of hepatitis B virus at points across the genome: Footprints of recombination in certain isolates
76. Long-term mutation rates in the hepatitis B virus genome
77. Mutation rate of the hepadnavirus genome
78. Viral dynamics in hepatitis B virus infection
79. Viral dynamics in vivo: Limitations on estimates of intracellular delay and virus decay
80. Emergence and take-over of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
81. Acyclovir- and ganciclovir-induced neurotoxicity
82. Animal models for hepatitis B infections - Duck hepatitis
83. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir
84. Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5'-triphosphates of various anti-HIV nucleoside analogs
85. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication
86. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: A novel system for screening potential inhibitors of HBV replication
87. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA
88. Hepadnavirus-induced liver cancer in woodchucks
89. The hepatitis B virus-trimera mouse: A model for human HBV infection and evaluation of anti-HBV therapeutic agents
90. Accumulation of genetic alterations in a human hepatoma cell line transfected with hepatitis B virus
91. Genotoxicity of 1,3- and 1,6-dinitropyrene: Induction of micronuclei in a panel of mammalian test cell lines
92. What is synergy?
93. The search for synergy: A critical review from a response surface perspective
94. In vitro antihepadnaviral activity of combinations of penciclovir, lamivudine and adefovir (PMEA)
95. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy
96. Significance testing of clinical data using virus dynamics models with a Markov chain Monte Carlo method: Application to emergence of lamivudine-resistant hepatitis; B virus
97. The use of ampligen alone and in combination with ganciclovir and coumermycin A1 for the treatment of ducks congenitally-infected with duck hepatitis B virus
98. Inhibition of duck hepatitis B virus DNA replication by antiviral chemotherapy with ganciclovir-nalidixic acid
99. Interaction between ganciclovir and foscarnet as inhibitors of duck hepatitis B virus replication in vitro
100. In vitro evaluation of combination therapies against hepatitis B virus replication
101. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro
102. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with [-]beta-L-2',3'-dideoxy-3'-thiacytidine
103. Robustaflavone, a potential non-nucleoside anti-hepatitis B agent
104. Effectiveness of combination therapies against hepatitis B virus (HBV) replication in vitro
105. Penciclovir and mycophenolic acid act synergistically as inhibitors of in vitro hepadnaviral replication
106. An open study of human lymphoblastoid interferon and oral acyclovir in chronic hepatitis B virus infection
107. Beta- and gamma-interferon in chronic active hepatitis B: A pilot trial of short-term combination therapy
108. Short-term prednisolone followed by recombinant human alpha-interferon alone or combined with adenine-arabinoside in chronic hepatitis B: A prospective and randomized trial
109. Therapy for chronic hepatitis B with lymphoblastoid interferon-alpha and levamisole
110. Levamisole and interferon in children with chronic hepatitis B
111. Interferon-alpha and zidovudine combination therapy for chronic hepatitis B: Results of a randomized, placebo-controlled trial
112. Alpha- and gamma-interferon versus alpha-interferon alone in chronic hepatitis B: A randomized controlled study
113. Pilot study of ribavirin and interferon-beta for chronic hepatitis B
114. Prednisone-intefferon combination in the treatment of chronic hepatitis B: Direct and indirect meta-analysis
115. Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: A randomized controlled trial
116. Combination low-dose lymphoblastoid interferon and thymosin alpha 1 therapy in the treatment of chronic hepatitis B
117. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection
118. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: Results of a pilot study
119. Combination therapy with famciclovir and interferon-alpha for the treatment of chronic hepatitis B
120. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
121. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy
122. Combination therapy with lamivudine and famciclovir for chronic hepatitis B infected Chinese: A viral dynamics study
123. Randomised trial in HBeAg negative patients with replicating virus with ganciclovir vs lamivudine in combination with interferon: Evaluation of long-term efficacy
124. Phase II clinical thai of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B
125. Highly active antiretroviral therapy used to treat concurrent hepatitis B and human immunodeficiency virus infections
126. Human immunodeficiency virus and hepatitis B virus co-infection in two siblings: Viral loads markedly reduced by triple-therapy including lamivudine
127. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus
128. Antiviral treatment for human immunodeficiency virus patients co-infected with hepatitis B virus: Combined effect for both infections, an obtainable goal?
129. HIV patients receiving HAART therapy can still transmit the virus: Highly active antiretroviral chemotherapy
130. Combination therapy for chronic hepatitis B